Glenmark Pharmaceutical Colombia SAS

Reporting Pack

Quarter ended

31 Mar 2025

IFRS Reporting Pack		
Entity:	**Glenmark Pharmaceuticals Colombia SAS**	
Year:	**31-mar-25**	31-3-2025
Currency	**COP**	
	Colombian Peso	
Prepared by	**Javier Castilla Robles**	
Reviewed by	**David Alonso Sandoval Rincon**	

Reporting Period	31-Mar-25
Transition Date	31-Mar-25
Fecha.corte.ant	31-Mar-24

Glenmark Pharmaceuticals Colombia SAS 53% 59%

Statement of Comprehensive Income

	Sch	31-Mar-25	31-Mar-24
		mar-25	mar-24
INCOME		COP	COP
Income from operations		17,842,367,051	14,983,871,029
Other income	S 6	741,774,937	1,266,941,325
Changes in inventories		-	-
TOTAL INCOME		**18,584,141,988**	**16,250,812,354**
Cost of materials	S 24		
Changes in inventories of finished goods and work-in-process	S 24	(2,912,371,894)	(756,336,904)
Purchase of products for sale	S 24	11,590,385,100	7,399,554,227
Employee benefit expenses		4,103,114,165	4,192,705,671
Depreciation, amortisation and impairment of non-financial assets		337,886,726	428,888,372
Research and Development expenses			
Other expenses	S 7	4,993,126,035	3,905,950,064
COSTS AND OPERATING EXPENSES		**18,112,140,132**	**15,170,761,430**
Operating profit		472,001,856	1,080,050,924
Share of profit from equity accounted investments		-	-
Finance costs		-	-
Finance income		-	-
Other financial expenses		-	-
Profit/(Loss) before tax		**472,001,856**	**1,080,050,924**
Income tax (expense)/credit		264,472,085	(3,048,518,823)
Profit/(Loss) after tax from continuing operations		**736,473,941**	**(1,968,467,899)**
Post tax profit/ (loss) for the year from discontinued operations		**-**	**-**
Profit/(Loss) after tax carried to balance sheet		**736,473,941**	**(1,968,467,899)**
Profit for the year attributable to:			
Non Controlling Interest			
Owners of the parent		**736,473,941**	**(1,968,467,899)**
Earnings per share			
Basic earnings per share			
Profit from continuing operations		-	-
Loss from discontinued operations		-	-
Total		**-**	**-**
Diluted earnings per share			
Profit from continuing operations		-	-
Loss from discontinued operations		-	-
Total		**-**	**-**

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

2-Financial Position

Statement of Financial Position	Sch	31-Mar-25	31-Mar-24
		COP	COP
ASSETS		IFRS	IFRS
Current assets			
Inventories		4,788,300,975	**1,875,929,081**
Trade receivables	S 8	7,143,090,148	4,029,844,071
Other short-term financial assets	S 2	1,412,522,358	1,330,041,837
Cash and cash equivalents	S 3	1,477,262,136	2,230,166,442
Restricted cash		-	-
Total current assets		**14,821,175,619**	**9,465,981,432**
Non current assets			
Property, plant and equipment		236,694,799	232,213,252
Other Intangible Assets	S 2 B	475,707,508	439,276,055
Deferred tax assets		3,978,642,000	3,978,642,000
Uses Deferred Tax-Current Tax Effect		-	-
Deferred assets - other		520,060,465	65,440,434
Restricted cash		-	-
Total non- current assets		**5,211,104,772**	**4,715,571,741**
Assets and disposal group classified as held for sale		-	-
Total assets		**20,032,280,390**	**14,181,553,173**
EQUITY AND LIABILITIES			
Liabilities			
Current liabilities			
Trade payables	S 19	9,998,160,664	5,459,040,784
Invoices payable with third parties		938,449,200	1,063,939,500
Other local accounts payable		415,369,662	346,216,846
Other current liabilities	**S 5**	540,235,534	76,640,909
Short Term Financial Liabilities	S 30	213,597,465	235,869,156
Total current liabilities		**12,105,812,525**	**7,181,707,195**
Non-current liabilities			
Other liabilities		-	-
Others-Deferred Tax Temporary differences		209,415,180	19,267,234
Total non-current liabilities		**209,415,180**	**19,267,234**
Liabilities included in disposal group held for sale		-	-
Total liabilities		**12,315,227,705**	**7,200,974,429**
Equity			
Equity attributable to owners of the parent:			
Share capital	S 4	26,174,737,750	26,174,737,750
Share Application Money (Pending Allotment)		-	-
APIC/ Share Premium		-	-
Retained earnings	S 4	(19,194,159,006)	(17,225,691,107)
Profit for the year		736,473,941	(1,968,467,899)
Reserves & Surplus		-	-
Currency translation reserve		-	-
Non Controlling Interest		-	-
Total Equity		**7,717,052,685**	**6,980,578,744**
Total Equity and Liabilities		**20,032,280,390**	**14,181,553,173**

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

3-Statement of Cash Flows

	COP	COP
	31-Mar-25	31-Mar-24
(A) Cash flow from operating activities		
Profit before tax	**472,001,856**	**1,080,050,924**
Adjustments for non cash items:		
Ammortisation - Brands / Intangibles	296,053,246	389,415,765
Depreciation	41,833,480	39,472,607
Deferred tax on temporary differences (accounting vs. tax)		
Non-deductible expenses (Non-recoverable customer values)	-	98,113,686
Impairment of goodwill		
Rent (unwinding of prepayments arisen on discounting long term security deposits at fair value)		
Interest expenses		
Unrealised gain on exchange fluctuation		
Provision for doubtful debts	-	-
Cash flows from operations before changes in working capital	**809,888,582**	**1,607,052,982**
Changes in operating assets and liabilities		
Non current liabilities, trade payables and other current liabilities	384,985,450	(152,034,137)
Intercompany movement- trade payables	4,539,119,880	1,123,356,300
Intercompany movement- other liablity	-	-
Others-Deferred Tax Temporary differences		19,267,234
Long term financial assets		
Trade receivables and unbilled revenue	(3,113,246,077)	(1,164,215,176)
Other current assets	(82,480,521)	(520,389,652)
Inventory Intercompany	(2,912,371,894)	(756,336,904)
Inventory Third Party		
Taxes paid		
Net cash generated from operating activities	**(374,104,580)**	**156,700,647**
(B) Cash flow from investing activities		
Purchase of property, plant and equipment	(46,315,027)	(91,522,139)
Purchase of other intangible assets	(332,484,699)	(132,101,039)
Proceeds from sale of property, plant and equipment		
Dividend received		
Net cash generated from/ (used in) investing activities	**(378,799,726)**	**(223,623,178)**
(C) Cash flows from financing activities		
Proceeds from issue of shares		
Proceeds from issue of shares-Intercompany	-	-
Pending for Analyisis		
Share Application Money (Pending Allotment)	-	-
Repayment of borrowings		
Interest paid on borrowings	-	-
Dividends paid		
Merger / Demerger and QIP expenses		
Net cash (used in)/ generated from financing activities	**-**	**-**
Net change in cash and cash equivalents from continuing operations	**(752,904,306)**	**(66,922,531)**
FCTR Adjustments		
Net change in cash and cash equivalents	**(752,904,306)**	**(66,922,531)**
Cash and cash equivalents at the beginning of the year	2,230,166,442	2,297,088,973
Cash and cash equivalents acquired on merger		
Effect of change in exchange rate on cash and cash equivalents included in disposal group		
Cash and cash equivalents at the end of the year	**1,477,262,136**	**2,230,166,442**

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

S 5
Deferred tax assets and liabilities

Deferred taxes arising from temporary differences and unused tax losses are summarized as follows:

(Amounts in COP)

	31-mar-24	Recognised in other comprehensive income	Recognised in business combination	Other movements, balance review	Adjustment of balances at a rate of 35%	Tax reversal (deferred tax)	Recognised in profit and loss account	Reverse deferred tax years 2017 and 2018	31-mar-25
Deferred tax assets									
Intangible assets									
Property, plants and equipments									
Retirement benefits and other employee benefits									
Straight lining of rent									
Minimum Alternative Tax credit entitlement									
Impact of change on tax rates from previous year									
Unused tax losses	3,978,642,000								3,978,642,000
Uses Deferred Tax-Current Tax Effect	0								-
Others-Deferred Tax Temporary differences	65,440,434						454,620,031.00		520,060,465
	4,044,082,434	**-**	**-**		**-**	**-**	**454,620,031**		**4,498,702,465**
Deferred tax liabilities									
Intangible liabilities									
Others-Deferred Tax Temporary differences	19267234						190,147,946		209,415,180
				-	**-**	**-**	**190,147,946**	**-**	**209,415,180**
Net deferred tax asset	**4,044,082,434**	**-**	**-**		**-**	**-**	**264,472,085**		**4,498,702,465**

5-Schedules 1 de 5

Schedule - S 11
Cost of materials

Particulars	31-Mar-25	31-Mar-24
	COP	COP
	IFRS	IFRS
Finished goods purchased	8,678,013,206	6,643,217,323
Total	**8,678,013,206**	**6,643,217,323**

Schedule - S 19

Trade payables		
Particulars	**31-Mar-25**	**31-Mar-24**
	COP	COP
	IFRS	IFRS
Sundry creditors	**10,936,609,864**	**5,459,040,784**
Glenmark India	9,998,160,664	5,222,201,412
Glenmark Argentina	-	-
Advances received / Glenmark Mexico	-	-
	-	-
Aztrazeneca(Col)	-	-
Invoices payable with third parties	938,449,200	236,839,372
Interest accrued but not due	-	
Employee dues	-	
Other liabilities		
Total	**10,936,609,864.00**	**5,459,040,784.00**

Schedule - S 24
Changes in inventories

Particulars	31-Mar-25	31-Mar-24
	IFRS	IFRS
Opening inventory	1,875,929,081	1,119,592,178
Closing inventory	4,788,300,975	1,875,929,081
Total	**(2,912,371,894)**	**(756,336,904)**

Trade payables	9,998,160,664
Invoices payable with third parties	938,449,200
Sub Total	10,936,609,864
Diferencia	-

Schedule - S 24
Cost of materials

Particulars		
	31-Mar-25	**31-Mar-24**
	IFRS	**IFRS**
Consumption of Raw and Packing material		
Opening Stock		
Add: Purchases		
Less: Closing stock		
Finished goods purchased	11,590,385,100	7,399,554,227
(Increase)/Decrease in Stock of Finished goods/WIP	(2,912,371,894)	(756,336,904)
Opening Stock		
-Work in progress		
-Finished goods		
Less: Closing Stock		
-Work in progress		
-Finished goods		
Consumption of stores and spares		
Consumption of stores and spares		
Total	**8,678,013,206**	**6,643,217,323**
Checks	**8,678,013,206**	**6643217323.2**
	-	0

5-Schedules 3 de 5

Schedule - 25
Employee benefit expenses

Particulars	mar-25	mar-24
	IFRS	IFRS
	IFRS	IFRS
Incentive Earnings (Reclasified)	261,285,214	314,915,738
Life Insurance Charges	174,476,349	156,234,094
Other benefit expenses (Gastos méd, guardería, Provision, Etc)	246,430,926	248,912,263
Salary and allowances	3,420,921,676	3,472,643,576
Total	**4,103,114,165**	**4,192,705,671**

5-Schedules 4 de 5

Schedule - S 7

Other expenses		
Particulars	**31-Mar-25**	**31-Mar-24**
Particulars	**COP** **IFRS**	**COP** **IFRS**
Unrealized Exchange Difference (Expense)	1,033,590,638.00	346,807,182.25
Other Selling Exps	1,046,378,603.46	615,756,702.95
Sales & Marketing Research	476,670,395.00	410,688,111.00
Total Profesional Fees Third Parties	-	-
Travelling Expenses	-	-
Conference expenses	131,028,813.00	204,645,277.00
Advertisement And Publicity	113,064,116.00	208,115,527.00
Samples	145,271,480.08	70,386,579.69
Office Premises Rent	85,468,684.00	75,885,712.00
Other Adm	155,299,781.31	180,033,580.67
Bank Charges	77,107,498.23	74,032,445.63
Trade Marketing & Sales Activities	147,874,599.00	207,021,685.00
Other (Gastos méd, guardería, Provision, Etc)	13,786,258.00	54,625,233.50
Sales Convention	10,221,975.00	85,390,224.00
Tax auditors	-	-
Professional Expenses	669,110,370.00	553,135,695.72
Insurance Charges	10,142,177.00	7,662,678.00
Ip Registration	-	-
Electricity Expenses	7,097,718.00	6,496,272.00
Power,Fuel,phone, internet, And Water Charges	8,645,884.01	10,183,105.47
Legal & Professional Expenses (Auditors Remuneration)	-	-
Realized Exchange Difference (Expense)	73,450,125.00	45,507,229.00
Cleaning service	13,614,654.00	10,978,150.00
Vehicle Maintenance	4,580,450.00	3,015,933.00
National / International Conference Exp.	-	-
Printing & Stationery	72,100.00	78,468.00
provision debtors	31,258,417.00	13,417,583.00
IVA DESCONTABLE POR PRORRATEO DE GASTOS	-	-
Audit fees - cost audit -Revisoría	36,294,528.00	33,212,424.00
expiration products	105,370,204.34	146,636,692.40
Field Staff Travelling expenses	238,989,256.30	232,991,119.94
Legal expenses	23,961,730.00	20,529,749.00
Other Regulatory Expenses	41,694,228.00	39,133,915.00
Other taxes	238,468,529.00	184,736,398.12
Travelling Expenses (No Sales Force)	39,243,254.46	59,994,964.53
Other expenses	15,369,568.70	4,851,426.00
Total	**4,993,126,035**	**3,905,950,064**
Other expenses	4,993,126,034.89	3,905,950,063.87
	-	-

5-Schedules 5 de 5

Schedule - S29

Profit/(Loss) before tax

Particulars	COP	COP
	31-Mar-25	31-Mar-24
	IFRS	IFRS
Current income tax		
MAT Credit	-	-
Deferred tax	-	(2,899,620,000)
Tax Temporary differences (accounting vs tax)	264,472,085	(148,898,823)
Prior period tax		
Wealth tax		
Total	**264,472,085**	**(3,048,518,823)**

6-S 6-Other Current Liabilities

S 6

Other current liabilities

Other current liabilities are summarized as follows:

	31-Mar-25	31-Mar-24
	COP	COP
	IFRS	IFRS
Share Application Money (Pending Allotment)		
Employee dues		
Statutory dues	-	-
Commission payable		
Deferred revenue		
Straight lining of rent		
Others	540,235,534	76,640,909
Invoices payable with third parties		
Values payable for taxes	**62,972,159**	**74,680,909**
Estimated liabilities	**473,575,068**	**1,960,000**
Customer payments- KAM review	**-**	**-**
Others	**3,688,307**	**-**
Total	**540,235,534**	**76,640,909**

7-S1 - Prop, Plant & Equipments

Property, plant and equipment

The Group's property, plant and equipment comprise freehold and leasehold land, IT and office equipment, and furniture and fixture. The carrying amount are analysed as

S 1

	Furniture and fixture	Equipment	Vehicles	AS11 Fixed asset	Capital work in progress	Total
Cost						
Balance at 31-03-2024	**106,246,149**	**126,070,579**	**151,900,000**	**-**	**-**	**384,216,728**
- Acquisitions through business combinations						-
- Other acquisitions	-	46,315,027	-			46,315,027
- Disposals/Transfers						-
- Translation adjustment			-			-
Balance at 31-3-2025	**106,246,149**	**172,385,606**	**151,900,000**	**-**	**-**	**430,531,755**
	106,246,149	***172,385,606***	***151,900,000***			430,531,755
Balance at 30-06-2023	**-**	**-**	**-**			**-**
- Acquisitions through business combinations						-
- Other acquisitions						-
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2025	**106,246,149**	**172,385,606**	**151,900,000**	**-**	**-**	**430,531,755**
	106,246,149	**172,385,606**	**151,900,000**			430,531,755
	-	-	-			-
Accumulated Depreciation						
Balance at 31-03-2024	**34,491,076**	**95,765,936**	**21,746,464**	**-**	**-**	**152,003,476**
- Depreciation charge for the year	7,481,707	14,743,076	19,608,697			41,833,480
- Impairment loss recognized						-
- Disposals/Transfers						-
- Translation adjustment			-			-
Balance at 31-3-2025	**41,972,783**	**110,509,012**	**41,355,161**	**-**	**-**	**193,836,956**
	41,972,783	**110,091,684**	**41,772,489**			
	-	417,328	(417,328)	-		
- Depreciation charge for the year						-
- Impairment loss recognized						-
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2025	**41,972,783**	**110,509,012**	**41,355,161**	**-**	**-**	**193,836,956**
	41,972,783	***110,091,684***	***41,772,489***			***193,836,956***
	-		**(417,328)**			

Carrying value

Balance at 31-03-2024	71,755,073	30,304,643	130,153,536	-	-	232,213,252
Balance at 31-3-2025	64,273,366	61,876,594	110,544,839	-	-	236,694,799
Balance at 31-3-2025	**64,273,366**	**61,876,594**	**110,544,839**	**-**	**-**	**236,694,799**

8-S2B-Other Intangible Assets

S 2 B

Other intangible assets

The Group's other intangible assets comprises of acquired computer softwares, website costs and softwares under development. The carrying amounts for the reporting periods under review are analysed as follows:

	Capital work in progress	Brands	B	C	Total
Cost					
Balance at 31-03-2024	2,030,785,051	-	-	-	2,030,785,051
- Internally developed	-				-
- Acquired through business combinations	-				-
- Other acquisitions	332,484,699				332,484,699
- Disposals/ Transfers	-				-
- Translation adjustment	-				-
Balance at 31-3-2025	**2,363,269,750**	**-**	**-**	**-**	**2,363,269,750**
- Internally developed					-
- Acquired through business combinations					-
- Other acquisitions					-
- Disposals/ Transfers					-
- Translation adjustment					-
Balance at 31-3-2025	**2,363,269,750**	**-**	**-**	**-**	**2,363,269,750**
Amortisation and impairment					
Balance at 31-03-2024	1,591,508,996	-	-	-	1,591,508,996
- Amortisation charge for the year	296,053,246				296,053,246
- Impairment loss					-
- Amotisation charge for dosposals/ transfers					-
- Translation adjustment					-
Balance at 31-3-2025	**1,887,562,242**	**-**	**-**	**-**	**1,887,562,242**
- Amortisation charge for the year					-
- Impairment loss					-
- Amotisation charge for dosposals/ transfers					-
- Translation adjustment					-
Balance at 31-3-2025	**1,887,562,242**	**-**	**-**	**-**	**1,887,562,242**

Carrying value

Balance at 31-03-2024	-	-	-	-	521,262,542
Balance at 31-3-2025	475,707,508	-	-	-	475,707,508
Balance at 31-3-2025	475,707,508	-	-	-	475,707,508

9-Comprehensive Income

-

Statement of Comprehensive Income	Sch	31-Mar-25	31-Mar-24
		mar-25	COP
		IFRS	IFRS
Profit for the year		**736,473,941**	**(1,968,467,899)**
Other comprehensive income:			
Cash flow hedging			
- current year gains (losses)			
- reclassification to profit or loss			
Available-for-sale financial assets			
- current year gains (losses)			
- reclassification to profit or loss			
Exchange differences on translating foreign operations			
Share of other comprehensive income of equity accounted investments			
- reclassification to profit or loss			
Share of other comprehensive income on fair valuation of financial assets/ liabilities			
reclassification to profit or loss			
Income tax relating to components of other comprehensive income			
Other comprehensive income for the period, net of tax			
Total comprehensive income for the period		**736,473,941**	**(1,968,467,899)**
Total Comprehensive Income attributable to:			
Non Controlling Interest			
Owners of the parent			

10-Statement Changes in Equity

Schedule S 4

Statement of Changes in Equity

[All amounts are stated in Columbian Peso, unless otherwise stated]

	Share Capital	Share Application Money	Capital redemption reserve	Retained earnings	Currency Translation Reserve	Total equity
Balance at 31-03-2024	**26,174,737,750**	**-**	**-**	**(19,194,159,006)**	**-**	**6,980,578,744**
Dividends				-		-
Dividend tax				-		-
Residual Dividend and Dividend Tax				-		-
Transfer to General Reserve				-	-	-
Lease hold land - Accumulated depn				-		-
Share Application Money (Pending Allotment)		-		-		-
FCCB Impact				-		-
GPL India ESOP impact				-		-
Transfer of exchange fluctuation reserve				-		-
Transactions with owners						-
Profit for the year				736,473,941		**736,473,941**
Other comprehensive income:						-
Cash flow hedging						-
- current year gains (losses)						-
- reclassification to profit or loss						-
Share Premium						-
Available-for-sale financial assets						-
- current year gains (losses)						-
- reclassification to profit or loss						-
						-
Exchange differences on translating foreign operations						-
Share of other comprehensive income of equity accounted investments						-
- reclassification to profit or loss						-
Income tax relating to components of other comprehensive income						-
Total comprehensive income for the year						-
Balance at 31-3-2025	**26,174,737,750**	**-**	**-**	**(18,457,685,065)**	**-**	**7,717,052,685**

11-S8-Trade Receivables 1 de 2

S 8

Trade receivables [other receivables can be merged here, if material]

The carrying amount of trade receivables are analysed as follows:

	COP	COP	INR in Millions	INR in Millions
Particulars	**mar-25**	**mar-24**	**mar-25**	**mar-24**
Gross value	7,143,090,148	4,029,844,071	142.86	80.60
Less: Allowance for credit losses			-	-
Net trade receivables	**7,143,090,148**	**4,029,844,071**	**142.86**	**80.60**
	-	-		
	-	-		

Ageing Schedule

Archivo fuente

Particulars	**Outstanding for following periods from due of payments**					**Total**
	Less than 6 months	**6 months - 1 year**	**1 - 2 years**	**2 - 3 years**	**More than 3 years**	
(i) Undisputed Trade Receivable - considered good	6,934,780,378	218,800,124	(10,490,353)	-	-	7,143,090,148
(ii) Undisputed Trade Receivable - which have significant increase in credit risk						-
(ii) Undisputed Trade Receivable - credit impaired						-
(iv) Disputed Trade Receivable - considered good						-
(v) Disputed Trade Receivable - which have significant increase in credit risk						-
(vi) Disputed Trade Receivable - credit impaired					-	-
	6,934,780,377.62	218,800,124.05	- 10,490,353.21	-	-	7,143,090,148.46
	97.08%	3.06%	-0.15%	0.00%	0.00%	100.00%

-

6	180
360	720
720	1,080

Closing AR	Not Due	0-30	30-60	60-90	90-180
7,143,090,148	5,810,962,009	199,962,465	(402,317,090)	601,688,186	724,484,808

Dec-22-Debtors (Less and More than 6M).xlsx • Guardado

11-S8-Trade Receivables 2 de 2

Marzo´2023

Ageing Schedule (INR)

Particulars	Outstanding for following periods from due of payments					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed Trade Receivable - considered good	138.70	4.38	- 0.21	-	-	142.86
(ii) Undisputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(ii) Undisputed Trade Receivable - credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivable - considered good	-	-	-	-	-	-
(v) Disputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivable - credit impaired	-	-	-	-	-	-
	138.70	4.38	- 0.21	-	-	142.86
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Previous year

Ageing Schedule (INR)

Particulars	Outstanding for following periods from due of payments					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed Trade Receivable - considered good	3,974,145,868.73	15,009,960.44	40,688,242.06	-	-	4,029,844,071.23
(ii) Undisputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(ii) Undisputed Trade Receivable - credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivable - considered good	-	-	-	-	-	-
(v) Disputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivable - credit impaired	-	-	-	-	-	-

12-S2Other Short Trm Fin Assets

Other short term financial assets	31-Mar-25	31-Mar-24
	COP	COP
Particulars	**IFRS**	**IFRS**
Cash Collateral		
Input taxes receivables	1,579,131,826	1,198,386,538
Import advances	-	-
Others	(166,609,468)	131,655,299
Total	**1,412,522,358**	**1,330,041,837**
	1,412,522,358	1,330,041,837
	-	-

13-S3-Cash & cash equivalents

S 3

Cash and cash equivalents

Cash and cash equivalents include the components as follows:	31-Mar-25	31-Mar-24
	COP	COP
	IFRS	IFRS
Cash in hand		-
Cash on hand		
Cheques in hand		
Cash in current accounts	1,477,262,136	2,230,166,442
Cash in deposit accounts		
Mutual fund deposit in liquid money market		
Fund-in-transit		
Total	**1,477,262,136**	**2,230,166,442**

	1,477,262,136	2,230,166,442
	-	-

14-S30Short Term FinancialLiabi

Short Term Financial Liabilities

Short Term Financial Liabilities are summarized as follows:	31-Mar-25	31-Mar-24
	COP	COP
	IFRS	IFRS
Employee dues	213,597,465	235,869,156
Statutory dues		
Commission payable		
Deferred revenue		
Straight lining of rent		
Others		
Total	**213,597,465**	**235,869,156**
	213,597,465	235,869,156
	-	-

15-S7 - Inventories

S 7

Inventories

Inventories recognised in the statement of financial position can be analysed as follows:

(Amounts in COP)

Particulars	March 31, 2025	March 31, 2024
Finished Goods	4,788,300,975	1,875,929,081
Others		
Total	**4,788,300,975**	**1,875,929,081**
Cifra control	4,788,300,975	1,875,929,081
Diferencia	-	-

16-S 7 - Income Taxes

Income taxes

Tax expense reported in income statement for the years ended :

	LCY	
	31-mar-25	31-mar-24
Current tax expense	-	-
Deferred tax credit	-	2,899,620,000
Uses Deferred Tax-Current Tax Effect	-	
Deferred assets - other	(264,472,085)	148,898,823
Net tax (expense)/credit	**(264,472,085)**	**3,048,518,823**
	264472085	-3048518823
Any adjustments recognised in the period for current tax of previous periods also need to be disclosed separately.	-	-

17-Related Party Trasactions

Glenmark Pharmaceuticals Colombia SAS			
Related party transactions			
	COP	INR IN MILLION	USD
Transactions during the year with group companies -			
Share Capital - Purchase of Share by Glenmark India	-	-	
Share Application Money - GPL India	-	-	
Purchases	-		(224,225.21)
Glenmark Pharmaceutical Ltd. - India	5,326,050,394	107	1,025,041
Received in warehouse (apr -Jun 2024)	1,188,967,222	23.78	286,633.50
Received in warehouse (Jul -Sep 2024)	1,175,570,433	23.51	282,303.35
Received in warehouse (Oct -Dec 2024)	1,360,319,241	27.21	296,664.54
Received in warehouse (Jan -Mar 2025)	661,113,610	13.22	(64,785.46)
	4,385,970,506	**88**	**800,816**
Inventory in transit (31 Mar 2025)	940,079,888	18.80	224,225.21
Credit notes	-	-	

Glenmark Pharmaceutical Ltd. Argentina	-	-	-
Purchases			
Received in warehouse (apr -Jun 2024)	22,973,168.00	0.46	5,929.60
Received in warehouse (Jul -Sep 2024)			
Received in warehouse (Oct -Dec 2024)			
Received in warehouse (Jan -Mar 2025)			
	22,973,168		**5,929.60**

Glenmark Pharmaceutical Ltd. Peru			

Bills paid			
Glenmark Pharmaceutical Ltd. - India	1,864,056,426	37.28	447,893
(Apr -Jun 2024)	895,186,188	17.90	217,975.59
(Jul -Sep 2024)	968,870,238	19.38	229,917.04
(Oct -Dec 2024)	-		-
(Jan -Mar 2024)			
Glenmark Pharmaceutical Ltd. Argentina	24,991,985	0.50	5,929.60
Glenmark Pharmaceutical Ltd. Peru			

Closing Balances- Payable for Purchases			
Glenmark Pharmaceutical Ltd. - India	**9,998,160,664**	**199.96**	**2,384,733.15**
Glenmark Pharmaceutical Ltd. Argentina	-	-	-
Glenmark Pharmaceutical Ltd. Peru	-	-	
ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 1	-	-	-
	9,998,160,664		2,384,733.15

220505	PROVEEDORES NACIONALES (Astrazeneca)	938,449,200	938449200	-
221005010	INDIA	9,998,160,664	9998160664	-
221005010	ARGENTINA	-	0	-
		10,936,609,864	10,936,609,864	-
		-		
Trade payables		10,936,609,864	10,936,609,864	-
Diferencia		-	-	-

18-Capital Mgt Pol & Proc.

Capital management policies and procedures

The Group’s capital management objectives are:

a) to ensure the Group's ability to continue as a going concern and

b) to provide an adequate return to shareholders.

The Group monitors gearing ratio i.e. total debt in proportion to its overall financing structure, i.e. equity and debt. Total debt comprises of all financial liabilities of the Group. The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets.

	31-mar-25	31-mar-24
Total equity	7,717,052,685	6,980,578,744
Total debts	-	-
Overall financing	**7,717,052,685**	**6,980,578,744**
Gearing ratio	0.000	-

If there are any externally imposed capital requirements, the same are also to be disclosed here.

Ratios

Particulars	Formula	As at March 31, 2025	As at March 31, 2024
Current Ratio	Current Assets / Current Liabilities	**1.22**	**1.32**
Debt-Equity Ratio	Borrowing / Shareholder's Equity	**-**	**-**
Debt Service Coverage Ratio	EBIT / (Borrowing + (1+Rate of Interest))	**-**	**-**
Return on Equity Ratio	Net Profit / Shareholder's Equity	**9.5%**	**-28.2%**
Inventory turnover ratio	COGS / ((Opening + Closing Inventory)/2)	**2.60**	**4.44**
Trade Receivables turnover ratio	Sales / ((Opening + Closing Trade Receivable)/2)	**3.19**	4.35
Trade payables turnover ratio	Purchases / ((Opening + Closing Trade Payable)/2)	**0.37**	0.38
Net capital turnover ratio	Net Sales / Shareholder's Equity	**1.78**	**2.74**
Net profit ratio	Net Profit / Sales	**4.1%**	**-13.1%**
Return on Capital employed	EBIT / Shareholder's Equity	**3.1%**	**5.8%**
Return on Investment	Net Profit / Shareholder's Equity	**2.8%**	**-7.5%**

Glenmark Phartmaceuticals Colombia SAS
Notes to the Standalone Financial Statements
(COP-Colombian)

NOTE 9 - CURRENT FINANCIAL ASSETS

(i) TRADE RECEIVABLES

Particulars	31/03/2025	31/03/2024
Unsecured		
Considered good * (Refer note 35)	7,143,090,148	4,029,844,071
Considered doubtful #	-	-
Allowance for doubtful debts/ expected credit losses #	-	-
Total	7,143,090,148	4,029,844,071
	7,143,090,148	4,029,844,071
	-	-

Ageing Schedule

Particulars	Outstanding for following periods from due of payments					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed Trade Receivable - considered good	6,934,780,377.62	218,800,124.05	(10,490,353.21)	-	-	7,143,090,148
(ii) Undisputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(ii) Undisputed Trade Receivable - credit impaired	-	-	-	-	-	-
(iv) Disputed Trade Receivable - considered good	-	-	-	-	-	-
(v) Disputed Trade Receivable - which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed Trade Receivable - credit impaired	-	-	-	-	-	-
						7,143,090,148
						-

Glenmark Phartmaceuticals Colombia SAS
Notes to the Standalone Financial Statements
(COP-Colombian)

Previous year
Ageing Schedule

Particulars	Outstanding for following periods from due of payments					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed Trade Receivable - considered good	3,974,145,868.73	15,009,960.44	40,688,242.06	-	-	4,029,844,071.23
(ii) Undisputed Trade Receivable - which have significant increase in						-
(ii) Undisputed Trade Receivable - credit impaired						-
(iv) Disputed Trade Receivable - considered good						-
(v) Disputed Trade Receivable - which have significant increase in credit risk						-
(vi) Disputed Trade Receivable - credit impaired						-

21-Note 12 -Share Capital

Glenmark Pharmaceuticals Limited
Notes to the Standalone Financial Statements
(COP-Colombian)

NOTE 12 - EQUITY SHARE CAPITAL	**As at**		As at	
Share capital	**31/03/2025**		**31/03/2024**	
	No. of Shares	**Amount**	**No. of Shares**	**Amount**
Authorised				
Equity Shares of Re 1 each	275,456	$ 275,456,000	275,456	$ 275,456,000
Cumulative redeemable non-convertible preference shares of Rs.100 each	-	-	-	-
Issued, subscribed and fully paid-up equity shares of Re 1 each				
At the beginning of the year	**275,456**	**275,456,000**	**275,456**	**275,456,000**
Add: Issued during the year	-	-	-	-
At the end of the year	**275,456**	**275,456,000**	**275,456**	**275,456,000**
		-		**275,456,000.00**
				-

List of shareholders holding more than 5 % shares	**31/03/2025**		**31/03/2024**	
	% of Holding	**No. of Shares**	**% of Holding**	**No. of Shares**
Saldanha Family Trust	-	-	-	-

22-Note 14 Trade Payables

Glenmark Pharmaceuticals Limited
Notes to the Standalone Financial Statements
(COP-Colombian)
(ii) TRADE PAYABLES

Particulars	31-mar-25	31-mar-24
Trade payables outstanding dues to Micro, small and medium enterprises under MSMED Act, 2006 [Refer note (i) below]	-	-
Trade payables	9,998,160,664.00	5,459,040,784.00
Invoices payable with third parties	938,449,200.00	1,063,939,500.00
Other local accounts payable	415,369,662.20	346,216,846.04
Trade payables outstanding dues to creditors other than micro, small and medium enterprises	-	-
Total	**11,351,979,526.20**	**6,869,197,130.04**
	11,351,979,526.20	6,869,197,130.04
	-	-
	-	-

Note (ii)
Ageing Schedule 45747

Particulars	Outstanding for following periods from due of payments #					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) MSME		-	-	-		-
Trade payables	5,780,471,173.00	1,004,221,809.00	2,437,446,454.00	716,285,155.00	59,736,073.00	9,998,160,664.00
Invoices payable with third parties	938,449,200.00	-	-	-	-	938,449,200.00
Other local accounts payable	415,369,662.20					415,369,662.20
(iii) Disputed dues - MSME	-	-	-	-		-
(iv) Disputed dues - Others	-	-	-	-		-
	7,134,290,035.20	1,004,221,809.00	2,437,446,454.00	716,285,155.00	59,736,073.00	11,351,979,526.20

11,351,979,526.20

-

01.-Por vencer	2,852,329,053		
02.-Ven : 1-30			
05.-Ven : 91-180	1,988,062,232		
06.-Ven :181-360	1,004,221,809		
07.-Ven : + 360	3,213,467,682		
	9,058,080,776.00	9,998,160,664.00	940,079,888.00
	9,998,160,664.00		
	940,079,888.00		

22-Note 14 Trade Payables

Glenmark Pharmaceuticals Limited
Notes to the Standalone Financial Statements
(COP-Colombian)

1 - 2 years	
2 - 3 years	
6 months - 1 year	12,713,051.00
Less than 6 months	1,668,919,907.00
More than 3 years	
	1,681,632,958.00

1 - 2 years	
2 - 3 years	
6 months - 1 year	
Less than 6 months	
More than 3 years	
	0.00

-

Ageing Schedule
Previous year (Mar'22)

Particulars	Outstanding for following periods from due of payments #					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Trade payables	1,059,426,235.00	522,749,756.00	1,444,738,727.00	-	2,432,126,066.00	5,459,040,784.00
Invoices payable with third parties	1,063,939,500.00	-	-	-	-	1,063,939,500.00
Other local accounts payable	346,216,846.04	-				346,216,846.04
(i) MSME						-
(ii) Others - Related Parties				-		-
(iii) Disputed dues - MSME	-	-	-	-		-
(iv) Disputed dues - Others	-	-	-	-		-
	-	-	-	-	-	6,869,197,130.04

-

Disclosure of Related Party Transactions for the half year ended **31/03/2025**

(Amount Lcy'000)

Sr.	Details of the Party (Listed entity/ Subsidiary entering into the transaction		Details of the counter party								In case monies are due to other party as result of transactions	
	Name	PAN/CIN	Name	PAN/CIN	Relationship of the counterparty with the listed entity or its subsidiary	Purchase of Goods and Services (Net of Returns)	Expenses paid on behalf of	Bills paid	Difference in change	Expenses Paid by others on our behalf	Opening Balance	Closing Balance
1	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. - India		Parent Company	6,266,130	-	1,864,056	(137,046)		5,459,041	9,998,161
2	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. Argentina		Fellow Subsidiary	22,973		24,992	(2,019)		-	-
3	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. Peru		Fellow Subsidiary		-				-	-
4	ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 14		ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 14228 USA)			-						-
5												-
6												-
7												-
8												-
9												-
10												-
11												-
											5,459,041	9,998,161

Schedule - L
Long term financial assets
Long term financial assets comprise of the following:

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Held-to-maturity financial assets		
Security deposits assets		
Bonds		
Available-for-sale financial assets		
Investments in listed and unlisted securities		
Others		
Long-term inter company loan		
Investments in Subsidiaries		
Total	-	-

Schedule - M
Trade payables

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Sundry creditors		
Inter Company creditors	9,998,160,664.00	5,459,040,784.00
Acceptances		
Total	**9,998,160,664**	**5,459,040,784**
	9,998,160,664.00	5,459,040,784.00
	-	-

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Invoices payable with third parties	938,449,200.00	1,063,939,500.00
Other local accounts payable	415,369,662.20	346,216,846.04
	-	-
Total	**1,353,818,862**	**1,410,156,346**
	1,353,818,862.20	1,410,156,346.04
	-	-

Schedule - N
Current tax liabilities

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Provision for Wealth Tax		
Provision for Tax		
Total	-	-

Schedule - O
Short-term borrowings

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Short-term borrwings		
Working capital facilites		
Total	-	-

Schedule - P
Current portion of borrowings

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Current portion of long-term borrowings		
Inter Company loan		
Total	-	-

Schedule - Q
Other liabilities
Other current liabilities are summarized as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Advances received from customer		
Others	540,235,534.00	76,640,909.00
Statutory dues	-	-
Accrued Expenses		
Share Application Money	-	-
Total	**540,235,534**	**76,640,909**
	540,235,534.00	76,640,909.00
	-	-

Schedule - R
Short-term financial liabilities
Other current liabilities are summarized as follows:

Particulars	31/03/2025	31/03/2024

	COP	COP
	IFRS	IFRS
Employee dues	213,597,465.00	235,869,156.00
Uncliamed dividend		
Interest accrued but not due		
Others		
Total	**213,597,465**	**235,869,156**
	213,597,465.00	235,869,156.00
	-	-

Schedule - S
Provisions

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Provision for compensated absences		
Provision for gratuity benefit plan		
Provision for Employee benefits		
Total	**-**	**-**

Schedule - T
Long Term Borrowing

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Notes payable		
Term loan from banks		
Inter company loan		
Total	-	-

Schedule - U
Other liabilities (Non-Current)

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Other liablilites		
Total	-	-

Schedule - V
Long term financial liabilities

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Security Deposits		
Others		
Total	-	-

Schedule - W
Equity

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Equity attributable to owners of the parent:		
Share capital	26,174,737,750.00	24,586,971,250.00
Add- Share issued during the previous year	-	1,587,766,500.00
Share Application Money		
Transactions with owners		
Share Premium		
Stock compensation reserve		
Statutory Reserve		
Capital redemption reserve		
Capital reserve		
Amalgamation reserve		
Currency translation reserve		
Reserve & Surplus		
Retained earnings		
Profit & Loss balance	(19,194,159,006.30)	(17,225,691,107.39)
Addition during the period	736,473,941.43	(1,968,467,898.91)
Current period profit		
Exchnage Fluctuation Reserve		
Components of Defined Employee benefit cost		
Transfer to General reserve		
General reserve		
Total	(18,457,685,064.87)	(19,194,159,006.30)
Non Controlling Interest		
Total Equity	**7,717,052,685.13**	**6,980,578,744**
	7,717,052,685.13	6,980,578,743.70
	0.00	(0.00)

Glenmark Phartmaceuticals Colombia SAS (0) 0

Statement of Financial Position	Sch	31/03/2025	31/03/2024
		COP	COP
ASSETS		IFRS	IFRS
Current assets			
Cash and cash equivalents	A	1,477,262,136	2,230,166,442
Restricted cash	B	-	-
Trade receivables	C	7,143,090,148	4,029,844,071
Inventories	D	4,788,300,975	1,875,929,081
Other short-term financial assets	E	(166,609,468)	131,655,299
Other current assets	F	1,579,131,826	1,198,386,538
Total current assets		***14,821,175,619***	***9,465,981,432***
Non current assets			
Property, plant and equipment	G	236,694,799	232,213,252
Other Intangible Assets	H	475,707,508	439,276,055
Goodwill	I	-	-
Non-current tax assets	J	-	-
Deferred tax assets	K	3,978,642,000	3,978,642,000
Uses Deferred Tax-Current Tax Effect		-	-
Deferred assets - other		520,060,465	65,440,434
Restricted cash	D	-	-
Long term financial assets	L	-	-
Total non - current assets		***5,211,104,772***	***4,715,571,741***
Total assets		***20,032,280,390***	***14,181,553,173***
EQUITY AND LIABILITIES			
Current liabilities			
Trade payables	M	9,998,160,664	5,459,040,784
Invoices payable with third parties		938,449,200	1,063,939,500
Other local accounts payable		415,369,662	346,216,846
Current tax liabilities	N	-	-
Short-term borrowings	O	-	-
Current portion of long term borrowings	P	-	-
Other Current liabilities	Q	540,235,534	76,640,909
Short-term financial liabilities	R	213,597,465	235,869,156
Provisions	S	-	-
Total current liabilities		***12,105,812,525***	***7,181,707,195***
Non-current liabilities			
Long-term financial liablities	V	-	-
Deferred tax liabilities	K	209,415,180	19,267,234
Total non-current liabilities		***209,415,180***	***19,267,234***
Total liabilities		***12,315,227,705***	***7,200,974,429***
Stockholders' equity			
Share capital	W	26,174,737,750	26,174,737,750
Merger consideration, pending allotment			
Share Premium		-	-
Stock compensation reserve		-	-
Statutory reserve		-	-
Currency translation reserve			
Retained earnings		(18,457,685,065)	(19,194,159,006)
Non Controlling Interest		-	-
Total stockholders' equity		***7,717,052,685***	***6,980,578,744***
Total equity and liabilities		**20,032,280,390**	**14,181,553,173**

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112. 194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharma
20-Abr-2025

Glenmark Phartmaceuticals Colombia SAS

Schedule - X
Income from operations

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Sale of goods and out licensing of Intangible assets	17,842,367,050.93	14,983,871,029.24
other operating revenue		
Income from services		
	17,842,367,050.93	14,983,871,029.24
	17,842,367,050.93	14,983,871,029.24
	-	-

Schedule - Y
Other income
Other income is summarised as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Dividend on short term investments		
Profit on sale of short term investments		
Profit on sale of fixed assets		
Exchange Gain		
Profit on Sale of Business		
Miscellaneous income	741,774,937.00	1,266,941,325.16
Total	741,774,937.00	1,266,941,325.16
	741,774,937.00	1,266,941,325.16
	-	-

Schedule - Z
Material Consumed

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Consumption of Raw Material		
Consumption of Packing Material		
Total	**-**	**-**

Schedule - Z
Changes in Inventory of FG and WIP

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Changes in Inventory of FG and WIP	(2,912,371,894.13)	(756,336,903.78)
Total	(2,912,371,894.13)	(756,336,903.78)
	(2,912,371,894.13)	**(756,336,903.78)**
	-	-

Schedule - Z
Purchase of Traded Goods

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Purchase of Traded Goods	11,590,385,099.74	7,399,554,227.02
Total	**11,590,385,099.74**	**7,399,554,227.02**

Schedule - AA
Employee benefit expenses

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Life Insurance Charges	174,476,349.00	
Other benefit expenses (Gastos méd, guardería, Provision, Etc)	246,430,926.00	

Salary and allowances	3,420,921,676.00	4,192,705,671.00
Incentive Earnings (Reclasified)	261,285,214.00	
Total	4,103,114,165.00	4,192,705,671.00
	4,103,114,165.00	4,192,705,671.00
	-	-

Schedule - AB
Other Expenses

Particulars	31/03/2025	31/03/2024
	COP	COP
Particulars	IFRS	IFRS
Unrealized Exchange Difference (Expense)	1,033,590,638.00	346,807,182.25
Other Selling Exps	1,046,378,603.46	615,756,702.95
Sales & Marketing Research	476,670,395.00	410,688,111.00
Professional Expenses	669,110,370.00	553,135,695.72
Conference expenses	131,028,813.00	204,645,277.00
Field Staff Travelling expenses	238,989,256.30	232,991,119.94
Travelling Expenses (No Sales Force)	39,243,254.46	59,994,964.53
Advertisement And Publicity	113,064,116.00	208,115,527.00
Samples	145,271,480.08	70,386,579.69
Office Premises Rent	85,468,684.00	75,885,712.00
Other Adm	155,299,781.31	180,033,580.67
Bank Charges	77,107,498.23	74,032,445.63
Trade Marketing & Sales Activities	147,874,599.00	207,021,685.00
Other (Gastos méd, guardería, Provision, Etc)	13,786,258.00	54,625,233.50
Sales Convention	10,221,975.00	85,390,224.00
Audit fees - cost audit -Revisoría	36,294,528.00	33212424
Audit fees - report.India	-	-
Legal & Professional fees	-	-
Insurance Charges	10,142,177.00	7,662,678.00
Other Regulatory Expenses	41,694,228.00	39,133,915.00
Electricity Expenses	7,097,718.00	6,496,272.00
Telephone & Telex Charges	-	-
Realized Exchange Difference (Expense)	73,450,125.00	45,507,229.00
Cleaning service	13,614,654.00	10,978,150.00
Vehicle Maintenance	4,580,450.00	3,015,933.00
National / International Conference Exp.	-	-
Water Charges	-	-
Printing & Stationery	72,100.00	78,468.00
provision debtors	31,258,417.00	13,417,583.00
IVA DESCONTABLE POR PRORRATEO DE GASTOS	-	-
expiration products	105,370,204.34	146,636,692.40
Legal expenses	23,961,730.00	20,529,749.00
Other taxes	238,468,529.00	184,736,398.12
Power,Fuel,phone, internet, And Water Charges	8,645,884.01	10,183,105.47
Other expenses	15,369,568.70	4,851,426.00
Total	4,993,126,034.89	3,905,950,063.87
	4,993,126,034.89	3,905,950,063.87
	-	-

Schedule - AC
Depreciation, amortisation and impairment of non-financial assets

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Depreciation, amortisation and impairment of non-financial assets	337,886,726.00	428,888,372.20
	337,886,726.00	428,888,372.20
	337,886,726.00	428,888,372.20
	-	-

Schedule - AD

Finance income

Finance income is analysed as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Interest income on		
Inter company balances		
Interest Income on Fixed Deposits		
Other Interest income		
Total	-	-

Schedule - AE

Finance costs

Finance costs is analysed as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
- Interest expense on short term borrowings		
Term loans		
Cash credit		
Interest Expense - Inter company		
Interest Expense - Others		
Other Financial Expenses		
Total	-	-

Schedule - AF

Income tax (expense)/credit

Particulars	31/03/2025	31/03/2024
	COP	COP
	IFRS	IFRS
Current income tax		
Deferred tax	(264,472,085.00)	3,048,518,823.00
Prior period income tax		
Total	(264,472,085.00)	3,048,518,823.00
	264,472,085.00	(3,048,518,823.00)
	-	-

Glenmark Phartmaceuticals Colombia SAS

Statement of Comprehensive Income	Sch	31/03/2025	31/03/2024
		COP	COP
INCOME		IFRS	IFRS
Operating Revenue	X	17,842,367,050.93	14,983,871,029.24
Other income	Y	741,774,937.00	1,266,941,325.16
Total		18,584,141,987.93	16,250,812,354.40
Materials consumed	Z		
Changes in Inventories of FG and WIP		(2,912,371,894.13)	(756,336,903.78)
Purchase of Traded Goods		11,590,385,099.74	7,399,554,227.02
Employee benefit expenses	AA	4,103,114,165.00	4,192,705,671.00
Other expenses	AB	4,993,126,034.89	3,905,950,063.87
Depreciation, amortisation and impairment of non-financial assets	AC	337,886,726.00	428,888,372.20
Total		18,112,140,131.50	15,170,761,430.31
Operating profit		472,001,856.43	1,080,050,924.09
Finance costs	AD	-	-
Finance income	AE	-	-
Profit/(Loss) before tax		472,001,856.43	1,080,050,924.09
Current tax expenses	AF	-	-
Deferred tax expenses	AF	264,472,085.00	(3,048,518,823.00)
Total Tax expenses		264,472,085.00	(3,048,518,823.00)
Profit/(Loss) after tax from continuing operations		**736,473,941.43**	**(1,968,467,898.91)**
		-	(0.00)

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

Glenmark Phartmaceuticals Colombia SAS

Schedule - S 1
Property, Plant and Equipment

Particulars	31/03/2025	31/03/2024
	COP	COP
Gross Block	430,531,755.00	384,216,728.00
less: Accumulated depreciation	193,836,956.20	152,003,476.20
Net Block	**236,694,798.80**	**232,213,251.80**
	236,694,798.80	232,213,251.80
	-	-

Particulars	31/03/2025	31/03/2024
	COP	COP
Capital work in progress		
Total	-	-

Schedule - S 2
Other Intangible assets

Particulars	31/03/2025	31/03/2024
	COP	COP
Gross Block	2,363,269,750.00	2,030,785,051.00
less: Accumulated depreciation	1,887,562,242.00	1,591,508,996.00
Net Block	**475,707,508.00**	**439,276,055.00**
	475,707,508.00	439,276,055.00
	-	-

Schedule - S 6
Deferred tax liabilities (net)

Particulars	31/03/2025	31/03/2024
Deferred tax liabilities (net)	COP	COP
Deferred tax liability relating to		
Depreciation on tangible and intangible assets		
	-	-
Deferred tax assets relating to		
Provision for doubtful debts and advances		
Expenses deductible in future years		
Others	4,498,702,465	4,044,082,434
	4,498,702,465	4,044,082,434
Deferred tax liabilities (net)	**(4,498,702,465)**	**(4,044,082,434)**
	4,498,702,465	4,044,082,434
	-	-

Schedule - S 8
Inventories
Inventories recognised in the statement of financial position can be analysed as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Finished goods	4,788,300,975.45	1,875,929,081.32
Goods in transit - Packing material		
Total	**4,788,300,975**	**1,875,929,081**
	4,788,300,975.45	1,875,929,081.32
	-	-

Schedule - S 10
Trade receivables
The carrying amount of trade receivables are analysed as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Secured, considered good		
Less: Allowance for bad and doubtful debts		
Unsecured, considered good	7,143,090,148.46	4,029,844,071.23
Less: Allowance for bad and doubtful debts	-	-
Doubtful		
Less: Allowance for bad and doubtful debts		
Debts due by directors or other officers		
Net trade receivables	**7,143,090,148**	**4,029,844,071**
	7,143,090,148.46	**4,029,844,071.23**
	-	**-**

Schedule - S 11
Cash and cash equivalents
Cash and cash equivalents include the components as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Cash and cash equivalents		
Balance with banks		
- Current accounts	1,477,206,673.30	2,230,093,225.34
- EEFC accounts		
- Deposits (less than 3 months)		
Cheque, drafts on hand		
Cash on hand	55,463.00	73,217.00
Total	**1,477,262,136**	**2,230,166,442**
	1,477,262,136.30	2,230,166,442.34
	-	-

Schedule - S 12
Other Short term financilal Assets

Particulars	31/03/2025	31/03/2024
	COP	COP
Others	(166,609,467.52)	
Total	**(166,609,468)**	**-**

Schedule - S 13
Other current assets

Particulars	31/03/2025	31/03/2024
	COP	COP
Capital advances		
Advances other than capital advances		
(b) Advances to related parties		
(c) Perpaide expenses		
(d)Import advances	-	
(e) Advances recoverable in cash or kind or for value to be received (Unsecured)		
(f) Input Tax Receivables	1,579,131,825.90	1,330,041,837.11
Advances to directors or other officers		

Total	**1,579,131,826**	**1,330,041,837**
	1,579,131,825.90	1,330,041,837.11
	-	-

Schedule - S 19
Trade payables

Particulars	31/03/2025	31/03/2024
	COP	COP
Trade payables	10,936,609,864.00	5,459,040,784.00
Total	**10,936,609,864**	**5,459,040,784**
	9,998,160,664.00	5,459,040,784.00
	938,449,200.00	-

Schedule - S 20
Other current liabilities
Other current liabilities are summarized as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Employee dues	213,597,465.00	235,869,156.00
Statutory dues	-	-
Liability for legal obligation		
Sundry creditors for capital goods		
Income received in advance		
Advance from customers		
Payable to related parties		
Other Liablilties	540,235,534.00	76,640,909.00
Invoices payable with third parties	938,449,200.00	1,063,939,500.00
Other local accounts payable	415,369,662.20	346,216,846.04
Total	**2,107,651,861**	**1,722,666,411**
	2,107,651,861.20	1,722,666,411.04
	-	-

Schedule - S 21
Provisions

Schedule - S 14
Share capital

Particulars	31/03/2025	31/03/2024
Share capital	**COP**	**COP**
Authorised		
Equity Shares of Re 1 each		
Cumulative redeemable non convertible preference shares of Rs.100 each		
Issued, subscribed and fully paid-up equity shares of Re 1 each		
At the beginning of the year	26,174,737,750.00	24,586,971,250.00
Add: Issued during the year		
- Under the Employee Stock Option Scheme, 2003 (ESOS)		
- Share Application Money	-	1,587,766,500.00
At the end of the year	**26,174,737,750**	**26,174,737,750**
Merger consideration, pending allotment		
Total	-	-
	26,174,737,750.00	26,174,737,750.00
	-	-

Surplus in statement of profit and loss		
At the beginning of the year	(19,194,159,006.30)	(17,225,691,107.39)
Add: Addition on account of amalgamation		
Add: profit for the year	736,473,941.43	(1,968,467,898.91)
Net profit available for appropriation	(18,457,685,064.87)	(19,194,159,006.30)
Currency Fluctuation Reserve		
Less: allocations and appropriations		
- Proposed dividend on equity shares		
- Tax on proposed dividend on equity shares		
- Residual dividend and dividend tax		
- Other Comprehensive Income		
- Transfer to general reserve		
At the end of the year	(18,457,685,064.87)	(19,194,159,006.30)
Balance carried to Balance Sheet	**(18,457,685,065)**	**(19,194,159,006)**
	(18,457,685,064.87)	(19,194,159,006.30)
	-	-

Glenmark Phartmaceuticals Colombia SAS (0) 0

Statement of Financial Position	Sch	31/03/2025	31/03/2024
		COP	COP
ASSETS		IFRS	IFRS
Non current assets			
Property, plant and equipment	S 1	236,694,798.80	232,213,251.80
Capital work-in-progress	S 1	-	-
Goodwill	S 3	-	-
Other Intangible Assets	S 2	475,707,508.00	439,276,055.00
Intangible Assets under development	S 2	-	-
Financial Assets			
(i) Investemnts	S 4	-	-
(ii) Loans and advances	S 5	-	-
Other Long term financilal Assets			
Deferred tax assets	S 6	3,978,642,000.00	4,044,082,433.94
Other non-current assets	S 7	520,060,464.94	-
Total non- current assets		*5,211,104,771.74*	*4,715,571,740.74*
Current assets			
Inventories	S 8	4,788,300,975.45	1,875,929,081.32
Financial Assets			
(i) Investements	S 9	-	-
(ii) Trade receivables	S 10	7,143,090,148.46	4,029,844,071.23
(iii) Cash and cash equivalents	S 11	1,477,262,136.30	2,230,166,442.34
Other Short term financilal Assets	S 12	(166,609,467.52)	-
Current tax assets		-	-
Other current assets	S 13	1,579,131,825.90	1,330,041,837.11
Total current assets		***14,821,175,618.59***	***9,465,981,432.00***
Total assets		*20,032,280,390.33*	*14,181,553,172.74*
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	S 14	26,174,737,750.00	26,174,737,750.00
Other Equity	S 14	(18,457,685,064.87)	(19,194,159,006.30)
APIC/ Share Premium	S 14	-	-
Liabilities			
Non-current liabilities			
Financial Liabilities			
(i) Borrowings	S 15	-	-
Deferred tax liabilities	S 6	-	-
Other non- current liabilities	S 16	-	-
Total non-current liabilities		-	-
Current liabilities			
Financial Liabilities			
(i) Borrowings	S 17	-	-
(ii) Other financial liabilities	S 18	-	-
(iii) Trade payables	S 19	9,998,160,664.00	5,459,040,784.00
Invoices payable with third parties		938,449,200.00	
Other local accounts payable		415,369,662.20	
Other current liabilities	S 20	753,832,999.00	1,722,666,411.04
Provisions	S 21	-	-
Others-Deferred Tax Temporary differences	S 22	209,415,180.00	19,267,234.00
Total current liabilities		*12,315,227,705.20*	*7,200,974,429.04*
Total liabilities		*12,315,227,705.20*	*7,200,974,429.04*
Total equity and liabilities		*20,032,280,390.33*	*14,181,553,172.74*

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

Glenmark Phartmaceuticals Colombia SAS

Schedule - S 23
Income from operations

Particulars	31/03/2025	31/03/2024
	COP	COP
Sale of products (including Excise Duty)	17,842,367,050.93	14,983,871,029.24
sale of services	-	-
other operating revenues	-	-
	17,842,367,050.93	14,983,871,029.24
	17,842,367,050.93	14,983,871,029.24
	-	-

Schedule - S 24
Other income
Other income is summarised as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Dividend received from Subsidiaries		
Dividend received from others - Non Trade Investment		
Exchange gain (net)		
Interest income		
Guarantee commission		
Profit on sale of fixed assets		
Labour charges income		
Miscellaneous income	741,774,937.00	1,266,941,325.16
Profit on sale of business		
Total	741,774,937.00	1,266,941,325.16
	741,774,937.00	1,266,941,325.16
	-	-

Schedule - S 25
Cost of material consumed

Particulars	31/03/2025	31/03/2024
	COP	COP
Consumption of raw material		
Consumption of packing material		
Consumables		
Total	-	-

Schedule - S 25
Purchases of stock-in-trade

Particulars	31/03/2025	31/03/2024
	COP	COP
Purchases of stock-in-trade	11,590,385,099.74	7,399,554,227.02
Total	11,590,385,099.74	7,399,554,227.02
	11,590,385,099.74	7,399,554,227.02
	-	-

Schedule - S 25
Changes in inventories of finished goods, work-in-process and stock-in-trade

Particulars	31/03/2025	31/03/2024
	COP	COP
(Increase)/Decrease in inventories of finished work-in-pr and stock-in-trade	(2,912,371,894.13)	(756,336,903.78)
Total	(2,912,371,894.13)	(756,336,903.78)
(Increase)/Decrease in stocks		
At year end		
Stock of finished goods		
Stock in trade		
Work in process		
	-	-
At the beginning of the year		
Stock of finished goods		
Stock in trade		
Work in process		
	-	-
Total	-	-
	(2,912,371,894.13)	(756,336,903.78)
	-	-

Schedule - 26
Employee benefit expenses

Particulars	31/03/2025	31/03/2024
	COP	COP
Life Insurance Charges	174,476,349.00	-
Other benefit expenses (Gastos méd, guardería, Provision, Etc)	246,430,926.00	-
Salary and allowances	3,420,921,676.00	4,192,705,671.00
Incentive Earnings (Reclasified)	261,285,214.00	-
	-	-
	-	-
Total	4,103,114,165.00	4,192,705,671.00
	4,103,114,165.00	4,192,705,671.00
	-	-

Schedule - S27
Finance costs
Finance costs is analysed as follows:

Particulars	31/03/2025	31/03/2024
	COP	COP
Interest		
- Inter Company		
- Others		
Dividend on redeemable preference share		
Exchange differences regarded as an adjustment to borrowing costs		
Other borrowing costs		
Total	**-**	**-**

Schedule - S 1 S 2
Depreciation, amortisation expenses

Particulars	31/03/2025	31/03/2024
	COP	COP
Depreciation on tangible assets	41,833,480.00	
Amortization and impairment on intangible assets	296,053,246.00	428,888,372.20
	337,886,726.00	428,888,372.20
	337,886,726.00	428,888,372.20
	-	-

Schedule - S 28
Other Expenses

Particulars	31/03/2025	31/03/2024
	COP	COP
Unrealized Exchange Difference (Expense)	1,033,590,638.00	346,807,182.25
Other Selling Exps	1,046,378,603.46	615,756,702.95
Sales & Marketing Research	476,670,395.00	410,688,111.00
Professional Expenses	669,110,370.00	553,135,695.72
Conference expenses	131,028,813.00	204,645,277.00
Field Staff Travelling expenses	238,989,256.30	232,991,119.94
Travelling Expenses (No Sales Force)	39,243,254.46	59,994,964.53
Advertisement And Publicity	113,064,116.00	208,115,527.00
Samples	145,271,480.08	70,386,579.69
Office Premises Rent	85,468,684.00	75,885,712.00
Other Adm	155,299,781.31	180,033,580.67
Bank Charges	77,107,498.23	74,032,445.63
Trade Marketing & Sales Activities	147,874,599.00	207,021,685.00
Other (Gastos méd, guardería, Provision, Etc)	13,786,258.00	54,625,233.50
Sales Convention	10,221,975.00	85,390,224.00
Audit fees - cost audit -Revisoría	36,294,528.00	33,212,424.00
Audit fees - report.India	-	-
Legal & Professional fees	-	-
Insurance Charges	10,142,177.00	7,662,678.00
Other Regulatory Expenses	41,694,228.00	39,133,915.00
Electricity Expenses	7,097,718.00	6,496,272.00
Telephone & Telex Charges	-	-
Realized Exchange Difference (Expense)	73,450,125.00	45,507,229.00
Cleaning service	13,614,654.00	10,978,150.00
Vehicle Maintenance	4,580,450.00	3,015,933.00
National / International Conference Exp.	-	-
Water Charges	-	-
Printing & Stationery	72,100.00	78,468.00
provision debtors	31,258,417.00	13,417,583.00
IVA Suppliers Cost	-	-
expiration products	105,370,204.34	146,636,692.40
Legal expenses	23,961,730.00	20,529,749.00
Other taxes	238,468,529.00	184,736,398.12
Power,Fuel,phone, internet, And Water Charges	8,645,884.01	10,183,105.47
(g) Other expenses	15,369,568.70	4,851,426.00
Total	4,993,126,034.89	3,905,950,063.87
	4,993,126,034.89	3,905,950,063.87
	-	-

Schedule - S29

Income tax (expense)/credit

Particulars	31/03/2025	31/03/2024
	COP	COP
Current income tax	-	-
Deferred tax	(264,472,085.00)	3,048,518,823.00
Total	(264,472,085.00)	3,048,518,823.00
	264,472,085.00	(3,048,518,823.00)
	-	-

Glenmark Phartmaceuticals Colombia SAS

Statement of Comprehensive Income	**Sch**	**31/03/2025**	**31/03/2024**
INCOME		**COP**	**COP**
Revenue from Operations	S 23	17,842,367,050.93	14,983,871,029.24
Other income	S 24	741,774,937.00	1,266,941,325.16
Total		18,584,141,987.93	16,250,812,354.40
Cost of materials consumed	S 25		
Purchase of Stock-in-Trade	S 25	11,590,385,099.74	7,399,554,227.02
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	S 25	(2,912,371,894.13)	(756,336,903.78)
Employee benefits expense	S 26	4,103,114,165.00	4,192,705,671.00
Finance costs	S 27	-	-
Depreciation and amortisation expense	S 1, 2	337,886,726.00	428,888,372.20
Other expenses	S 28	4,993,126,034.89	3,905,950,063.87
Total		18,112,140,131.50	15,170,761,430.31
Profit/(loss) before exceptional items and tax		472,001,856.43	1,080,050,924.09
Exceptional Items		-	-
Profit/(Loss) before tax		472,001,856.43	1,080,050,924.09
Tax expense:	S 29		
(i) Current tax			
(ii) Deferred tax		(264,472,085.00)	3,048,518,823.00
Profit/(Loss) for the period from continuing operations		**736,473,941.43**	**(1,968,467,898.91)**
Post tax profit/ (loss) from discontinued operations			
Tax expens of discontinued operations			
Post tax profit/ (loss) from discontinued operations (after tax)			
Profit/(loss) for the period:			
Non Controlling Interest			
Owners of the parent			

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

Glenmark Phartmaceuticals Colombia SAS
Standalone Balance Sheet
(COP-Colombian)

		As at	As at	
ASSETS	**Notes**	**31-mar-25**	**31-mar-24**	
Non-current assets				
Property, plant and equipment	**3**	236,694,799	232,213,252	
Capital work-in-progress	**3**	0	0	
Intangible assets	**4**	475,707,508	439,276,055	
Intangible assets under development	**4**	0	0	
Financial assets	**5**			
i. Investments		0	0	
ii. Loans		0	0	
iii. Other financial assets		0	0	
Deferred tax assets (net)	**6**	3,978,642,000	3,978,642,000	
Other non-current assets - Right to Use	**7**	520,060,465	65,440,434	
Total non-current assets		**5,211,104,772**	**4,715,571,741**	
Current assets				
Inventories	**8**	4,788,300,975	1,875,929,081	
Financial assets	**9**			
i. Trade receivables		7,143,090,148	4,029,844,071	
ii. Cash and cash equivalents		1,477,262,136	2,230,166,442	
iii. Bank balances other than cash and cash equivalents		0	0	
iv. Other financial assets		0	0	
Other current assets	**10**	1,412,522,358	1,330,041,837	
Total current assets		**14,821,175,619**	**9,465,981,432**	
Total assets		**20,032,280,390**	**14,181,553,173**	
EQUITY AND LIABILITIES				
Equity				
Equity share capital	**11 & 12**	7,717,052,685	6,980,578,744	
Other equity		0		
Total equity		**7,717,052,685**	**6,980,578,744**	
LIABILITIES				
Non-current liabilities				
Financial liabilities	**13**			
i. Lease liabilities				
ii. Borrowings				
iii. Other financial liabilities				
Total non-current liabilities		**0**	**0**	
Current liabilities				
Financial liabilities	**14**			
i. Lease liabilities		0		
ii. Borrowings		0	0	
iii. Trade payables		9,998,160,664	5,459,040,784	
Invoices payable with third parties		938,449,200	1,063,939,500	
Other local accounts payable		415,369,662	346,216,846	
- Total outstanding dues of Micro enterprises and Small enterprises		0	0	
- Total outstanding dues of other than Micro enterprises and Small enterprises		0	0	
iii. Other current financial liabilities				**99,509**
Other current liabilities	**15**	540,235,534	76,640,909	
Short Term Financial Liabilities	**16**	213,597,465	235,869,156	
Provisions				
Others-Deferred Tax Temporary differences		209,415,180	19,267,234	
Total current liabilities		**12,315,227,705**	**7,200,974,429**	
Total liabilities		**12,315,227,705**	**7,200,974,429**	
Total equity and liabilities		**20,032,280,390**	**14,181,553,173**	
		(0)	(0)	

See accompanying notes to the financial statements.

As per our report of even date.

Preparado por
CASTILLA ROBLES JAVIER
CERTIFIED PUBLIC ACCOUNTANT
TP # 112.194-T

José Javier Fonseca Panche
Component Audit Partner: Glenmark Pharmaceuticals Colombia SAS
20-Abr-2025

4 **Glenmark Phartmaceuticals Colombia SAS**
Statement of Changes in Equity for the year ended
(COP-Colombian)

A Equity share capital

Particulars	Amount
31/03/2024	**275,456**
- Shares issued during the year	-
31/03/2025	**275,456**
- Shares issued during the year	-
31-mar-25	**275,456**

Refer notes 11 and 12 for details on equity share capital

B Other equity

Particulars	Reserves and Surplus						Total
	Securities premium	Additional value shares	Capital redemption reserve	Stock compensation reserve	General reserve	Retained earnings	
31/03/2024	**275,456,000.00**	**25,899,281,750**	-	-	-	**(18,457,685,064.87)**	**7,717,052,685.13**
Profit for the period	-	-	-	-	-		-
Other comprehensive income - Remeasurement of the net defined benefit plans (net of tax) (refer note 26)	-	-	-	-	-	-	-
Total comprehensive income for the year	-	-	-	-	-	-	-
Dividends to equity shareholders	-	-	-	-	-	-	-
Employee share based compensation expense (refer note 12(VI))	-	-	-	-	-	-	-
Share Application Money (Pending Allotment)	-						-
	-	-	-	-	-	-	-
31-mar-25	**275,456,000.00**	**25,899,281,750**	-	-	-	**(18,457,685,064.87)**	**7,717,052,685.13**

Particulars	Reserves and Surplus						Total
	Securities premium	Additional value shares	Capital redemption reserve	Stock compensation reserve	General reserve	Retained earnings	
31/03/2024	**275,456,000.00**	**25,899,281,750**	-	-	-	**(19,194,159,006)**	**6,980,578,743.70**
Profit for the period	-	-	-	-	-	736,473,941.43	**736,473,941.43**
Other comprehensive income - Remeasurement of the net defined benefit plans (net of tax) (refer note 26)	-	-	-	-	-	-	-
Total comprehensive income for the year	-	-	-	-	-	736,473,941.43	**736,473,941.43**
Dividends to equity shareholders (including dividend distribution tax)	-	-	-	-	-	-	-
Employee share based compensation expense (refer note 12(VI))	-	-	-	-	-	-	-
Share Application Money (Pending Allotment)	-	-	-	-	-	-	-
31-mar-25	**275,456,000.00**	**25,899,281,750**	-	-	-	**(18,457,685,064.87)**	**7,717,052,685.13**

See accompanying notes to the financial statements.

As per our report of even date.

33.00

0 0
0 0

GLENMARK PHARMACEUTICALS COLOMBIA SAS
NIT 900.246.528

AUDIT REPORT

AT AS Mar, 2025

Content

JOSE JAVIER FONSECA PANCHE
CONTADOR PÚBLICO
ASESORIAS CONTABLES
TRIBUTARIAS Y FINANCIERAS
REVISORIAS FISCALES Y AUDITORIAS
Email:javierfons@hotmail.com

Annual Review of Financial Statements

To the Shareholders and Directors of
Glenmark Pharmaceuticals Colombia SAS
Nit 900246528-8

1. We have reviewed the accompanying Balance sheet of Glenmark Pharmaceuticals Colombia SAS S.A ("the Company"), and related statement of Income, changes in equity and cash flow statement er ended **31 Mar 2025** ("the Statement)

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the International Financial Reporting Standard issued by the International Accounting Standards Board. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the International Standard on Review engagement 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity / Standard on Review Engagements (SRE) 2410 '**Annual Review of Financial Statements"** Information in accordance with international standard Board on review engagements approved for application in Colombia by Junta de Junta Central de Contadores(JCC). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is less in scope than an audit conducted in accordance with International Standard on Auditing / Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, was not prepared in accordance with the recognition and measurement principles laid down in the aforesaid International Accounting Standards Board and other accounting principles generally accepted by Junta de Contadores Públicos de Colombia(JCC), or that it contains any material misstatement.

JOSE JAVIER FONSECA PANCHE
Profesional card # 180 909-T
Independent Auditor
Bogotá Colombia, 24 Apr 2025